Meyer Handelman Co. Trims Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Meyer Handelman Co. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,119 shares of the biopharmaceutical company’s stock after selling 141 shares during the quarter. Meyer Handelman Co.’s holdings in Regeneron Pharmaceuticals were worth $2,934,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth about $26,000. Fairfield Financial Advisors LTD purchased a new position in Regeneron Pharmaceuticals during the third quarter worth about $37,000. Ashton Thomas Private Wealth LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter worth about $39,000. Finally, Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at about $39,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Evercore ISI cut their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Bank of America reiterated an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Barclays cut their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $1,032.57.

Regeneron Pharmaceuticals Stock Down 3.6 %

REGN opened at $690.87 on Wednesday. The firm has a market cap of $75.92 billion, a P/E ratio of 17.10, a PEG ratio of 2.19 and a beta of 0.10. The business’s fifty day simple moving average is $746.43 and its 200 day simple moving average is $956.18. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.